Skip to main content

CARACTERIZAR EL ESTRES TRANSCRIPCIONAL Y EL DE REPLICACION INDUCIDOS POR LA SOBREEXPRESION DE CICLINA D1 EN CELULAS B, RELEVANCIA EN LA PATOGENESIS DEL LCM Y POTENCIALES IMPLICACIONES TERAPEUTICAS

PI19/01838

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
Execution centre INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cyclin D1 Overexpression Predicts Poor Disease-Specific Survival in Human Papillomavirus-Independent Vulvar Squamous Cell Carcinoma

  • Carreras-Dieguez, Núria|||0000-0002-4809-8102
  • Ordi, Oriol
  • Peñuelas, Núria|||0000-0001-6443-9790
  • del Pino, Marta|||0000-0003-2178-2403
  • Diez-Ahijado, Laia
  • Darecka, Katarzyna
  • Marimón, Lorena|||0000-0002-2943-3550
  • Vega, Naiara
  • Torne, Aureli|||0000-0003-4700-9507
  • Saco, Adela
  • Albero Gallego, Robert|||0000-0001-5527-0997
  • Gaba, Lydia
  • Rakislova, Natalia|||0000-0001-5030-3526
The amplification of CCND1 is associated with the development and progression of various cancers. In a recent study, we showed that almost all adverse outcomes in vulvar squamous cell carcinomas (VSCC) occurred in patients with human papillomavirus (HPV)-independent, TP53-mutated tumors harboring CCND1 gains. In this study, we analyzed the association between CCND1 gain, cyclin D1 immunohistochemistry (IHC), and disease-specific survival (DSS) in a series of patients with HPV-independent VSCC. All patients who underwent primary surgery for VSCC at the Hospital Clínic of Barcelona, Spain, from 1975 to 2023 were recruited ("overall" cohort, n = 139). IHC for p53 and cyclin D1 was performed in all cases. In a subset of patients, we performed DNA sequencing to evaluate CCND1 copy number variations ("sequencing" cohort, n = 54). Cyclin D1 IHC overexpression (≥50% of tumor cells) had 94% sensitivity and 67% specificity as a surrogate marker of CCND1 gain. In the "sequencing" cohort, only CCND1 gains were significantly associated with impaired DSS in the multivariate analysis (hazard ratio [HR], 4.15; 95% CI, 1.08-5.40; P =.032), whereas stage or mutant TP53 status did not reach statistical significance. In the "overall" cohort, advanced stage (HR, 2.41; 95% CI, 1.08-5.39; P =.032) and cyclin D1 IHC overexpression (HR, 4.89; 95% CI, 1.77-18.5; P =.001) were associated with worse DSS in the multivariate analysis, whereas abnormal p53 IHC was not (HR, 5.06; 95% CI, 0.68-647; P =.138). In conclusion, cyclin D1 overexpression is an acceptable surrogate for CCND1 gain and has a much stronger adverse prognostic impact than altered p53 IHC in patients with HPV-independent VSCC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma

  • Demajo, Santiago
  • Albero Gallego, Robert|||0000-0001-5527-0997
  • Clot, Guillem|||0000-0003-2588-7413
  • Castellano, Giancarlo|||0000-0002-5715-7733
  • Navarro, Alba|||0000-0002-4041-0974
  • Capdevila, Cristina
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Giné, Eva|||0000-0002-0532-1204
  • Pinyol, Magda
  • Jaffe, E.S.
  • Ott, German|||0000-0001-7990-6793
  • Staudt, L.M.
  • Rosenwald, Andreas|||0000-0001-7282-8374
  • Scott, D.W.
  • Rimsza, L.M.
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Bea, Sílvia|||0000-0001-7192-2385
  • Campo, Elias|||0000-0001-9850-9793
  • Jares, Pedro
Purpose: Mantle cell lymphoma (MCL) is characterized by the t(11;14)(q13;q32) translocation leading to cyclin D1 overexpression. Cyclin D1 is a major cell-cycle regulator and also regulates transcription, but the impact of cyclin D1-mediated transcriptional dysregulation on MCL pathogenesis remains poorly understood. The aim of this study was to define a cyclin D1-dependent gene expression program and analyze its prognostic value. Experimental Design: We integrated genome-wide expression analysis of cyclin D1-silenced and overexpressing cells with cyclin D1 chromatin-binding profiles to identify a cyclin D1-dependent transcriptional program in MCL cells. We analyzed this gene program in two MCL series of peripheral blood samples (n ¼ 53) and lymphoid tissues (n ¼ 106) to determine its biological and clinical relevance. We then obtained a simplified signature of this program and evaluated a third series of peripheral blood MCL samples (n ¼ 81) by NanoString gene expression profiling to validate our findings. Results: We identified a cyclin D1-dependent transcriptional program composed of 295 genes that were mainly involved in cell-cycle control. The cyclin D1-dependent gene program was overexpressed in MCL tumors directly proportional to cyclin D1 levels. High expression of this program conferred an adverse prognosis with significant shorter overall survival of the patients. These observations were validated in an independent cohort of patients using a simplified 37-gene cyclin D1 signature. The cyclin D1-dependent transcriptional program was also present in multiple myeloma and breast tumors with cyclin D1 overexpression. Conclusions: We identified a cyclin D1-dependent transcriptional program that is overexpressed in MCL and predicts clinical outcome.